TABLE 3.
Association of the MTHFR (rs1801133) polymorphism with risk of developing HTN.
| SNP | Hypertensive (n; %) | Non-hypertensive (n; %) | Crude odds ratios (95%CI) | p-Value | Adjusted odds ratios (95%CI) | p-Value |
|---|---|---|---|---|---|---|
| rs1801133 (HWE, p = 0.069) | ||||||
| Genotypic | ||||||
| CC | (254; 91) | (144; 89) | 1.0* | 1.0* | ||
| CT | (21; 8) | (18; 11) | 0.64 (0.33–1.25) | 0.19 | 0.75 (0.29–1.95) a | 0.56 |
| TT | (3; 1) | (0; 0) | - | - | - | - |
| Dominant | ||||||
| CC | (254; 91) | (144; 89) | 1.0* | 1.0* | ||
| CT + TT | (24; 9) | (18; 11) | 0.75 (0.40–1.43) | 0.34 | 0.86 (0.35–2.16) a | 0.75 |
| Recessive | ||||||
| CC + CT | (275; 99) | (162; 100) | 1.0* | 1.0* | ||
| TT | (3; 1) | (0; 0) | - | - | - | - |
| Co-dominant | ||||||
| CC + TT | (18; 8) | (22; 11) | 1.0* | 1.0* | ||
| CT | (144; 92) | (256; 89) | 1.48 (0.72–2.84) | 0.24 | 1.33 (0.51–3.48) a | 0.55 |
| Allelic | ||||||
| C | (529; 95) | (306; 95) | 1.0* | |||
| T | (27; 5) | (18; 5) | 0.86 (0.47–1.60) | 0.65 |
a
adjusted for age, gender, smoking status, BMI and blood glucose levels.
*p-Value > 0.05 was considered statistically not significant.
HWE, Hardy-Weinberg Equilibrium; MTHFR, methylenetetrahydrofolate reductase; BMI, body mass index; CI, confidence interval.